Skip to main content
Different B cells depletion strategies in SARDs highlighted by Georg Schett

From low and short lived depletion achieved

Aurelie Najm AurelieRheumo

1 year ago
Different B cells depletion strategies in SARDs highlighted by Georg Schett From low and short lived depletion achieved w/ drugs to sustained deep tissular depletion with CAR T cells leading to potential immune reset @RheumNow #APLAR25 https://t.co/t35lrzEomF
Juvenile Lupus: some new mechanistic data

Circulating Treg population are expanded in SLE and in particular in Lupus Ne

Aurelie Najm AurelieRheumo

1 year ago
Juvenile Lupus: some new mechanistic data Circulating Treg population are expanded in SLE and in particular in Lupus Nephritis compared to HC Naive Treg display specific molecular features in particular over expression of FCRL3 and TLR5 showing new pathways to explore in https://t.co/RuMtWRkpYB
PAH, when associated with ILD in CTD, worsens prognosis, and poses challenges for treatment

Summary of when PAH should

Aurelie Najm AurelieRheumo

1 year ago
PAH, when associated with ILD in CTD, worsens prognosis, and poses challenges for treatment Summary of when PAH should be assessed in patients with ILD and when to perform a right heart catheterization by Prof Kuwana @RheumNow #APLAR25 https://t.co/g4x4ENzc9k
Dr. Alberta Hoi graphically presents the difference bet acute confusional states & chronic cognitive changes in #lup

sheila RHEUMarampa

1 year ago
Dr. Alberta Hoi graphically presents the difference bet acute confusional states & chronic cognitive changes in #lupus patients presenting with NP symptoms. NPSLE continues to pose a diagnostic challenge bec pts may present with more than one syndrome complex @RheumNow #APLAR25 https://t.co/4nYTo1fzVz
How to treat CTD ILD?

A comparative slide summarizing ACR/BSR and EULAR treatment guidelines

Emphasis on combination

Aurelie Najm AurelieRheumo

1 year ago
How to treat CTD ILD? A comparative slide summarizing ACR/BSR and EULAR treatment guidelines Emphasis on combination of Immunosuppressant and Antifibrotics @RheumNow #APLAR25 https://t.co/gLSht6QKh5
“Listen to the patient, he is telling you the diagnosis”. – Sir William Osler

Dr. John Cush RheumNow

1 year ago
“Listen to the patient, he is telling you the diagnosis”. – Sir William Osler
A framework for treatment stratified approach in CTD-ILD, by Dr Low Hsiu Ling

Based on
-ILD extent
-Risk of progressio

Aurelie Najm AurelieRheumo

1 year ago
A framework for treatment stratified approach in CTD-ILD, by Dr Low Hsiu Ling Based on -ILD extent -Risk of progression -Biology: fibrosis/inflammation -Safety -Other manifestations @RheumNow #APLAR25 https://t.co/ma5KugzBHy
Why shall we screen all patients with SSc for ILD?

Focusing screening strategy on patients « at risk » misses 25% o

Aurelie Najm AurelieRheumo

1 year ago
Why shall we screen all patients with SSc for ILD? Focusing screening strategy on patients « at risk » misses 25% of patients with ILD ILD being the main cause of mortality in SSc @RheumNow #APLAR25 https://t.co/djzCTdZoVb
The overall prevalence of #osteoporosis in SLE is ~33-40% and is due to several factors with GC therapy being one of the

sheila RHEUMarampa

1 year ago
The overall prevalence of #osteoporosis in SLE is ~33-40% and is due to several factors with GC therapy being one of them. Monitor DXA every 6-12 months (vs. 2 yrs for standard OP) ☝️Screen for GIOP ☝️Treat accordingly - once on GCs & esp w/long-term use @RheumNow #APLAR25 https://t.co/E9FJDHrBUo
Paradigm shift in CTD PAH

-Early triple therapy in patients with intermediate and high risk
-Sotatercept,
a blocker of

Aurelie Najm AurelieRheumo

1 year ago
Paradigm shift in CTD PAH -Early triple therapy in patients with intermediate and high risk -Sotatercept, a blocker of activin-Smad2/3 signaling have increased survival importantly Data presented by Dr Khanna @RheumNow #APLAR25 https://t.co/Z4yA6DwtOb
An important message from Prof. @XBaraliakos on D2M-axSpA:
Re-evaluate your diagnosis & check for comorbids before

sheila RHEUMarampa

1 year ago
An important message from Prof. @XBaraliakos on D2M-axSpA: Re-evaluate your diagnosis & check for comorbids before labelling pts as tx-refractory or difficult-to-manage. consider other causes: FM, other causes of pain @RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/Lo0yShOK0P
Drivers of costs associated with economic costs of RMDs in Asia Pacific

-Traditional medicine
-Loss of income much high

Aurelie Najm AurelieRheumo

1 year ago
Drivers of costs associated with economic costs of RMDs in Asia Pacific -Traditional medicine -Loss of income much higher if worker as opposed to unpaid household labor so high impact of gender roles -Impact of out of pocket health payments due to « catastrophic spendings » in https://t.co/sptwGE7J2V
Prof. Aletaha shares their AutoPiX project - using AI to develop quantitative biomarkers.

Something to look forward to

sheila RHEUMarampa

1 year ago
Prof. Aletaha shares their AutoPiX project - using AI to develop quantitative biomarkers. Something to look forward to since imaging remains an important diagnostic tool in #rheumatology @RheumNow #APLAR25 @rheumarhyme https://t.co/WExT9amazz
Update on Rheumatology workforce shortage in Asia-Pacific

Date presented by Dr Ahmad
Number of Rheumatologists per 1000

Aurelie Najm AurelieRheumo

1 year ago
Update on Rheumatology workforce shortage in Asia-Pacific Date presented by Dr Ahmad Number of Rheumatologists per 100000 inhabitants across @APLAR_org countries -3 in Japan -1.3 in Australia, Hong Kong, Singapore -0.03 in Pakistan As a result: delayed diagnosis for patients! https://t.co/Hycqtp8BtY
×